Medicare to Expand Coverage for PET Scans in Alzheimer’s Diagnosis Medicare will now provide broader access to PET scans, a valuable tool in diagnosing Alzheimer’s disease. The Centers for Medicare and Medicaid Services (CMS) announced in a recent memo that they would remove the once-in-a-lifetime limit previously imposed on PET scans. However, the decision on …
It is anticipated that the announcement of next year’s Medicare Part B premiums will be made soon, and there is speculation that the coverage of another expensive new Alzheimer’s medication, Leqembi, could lead to an increase in monthly costs, similar to what happened in 2022. In July, Leqembi received full approval from the Food and …
1 of 6 | A groundbreaking study reveals that loneliness could potentially increase the risk of developing Parkinson’s disease, the second most prevalent neurodegenerative condition worldwide. This finding is supported by a research article published in JAMA Neurology. View the research image taken by Lucas Rychvalsky/Pixabay. New YORK, Oct. 2 (UPI) — According to a …
Billionaire Bill Gates has had a change of heart when it comes to the importance of sleep. Previously, Gates viewed sleep as lazy and unnecessary, bragging about how little sleep he needed during his prime years at Microsoft. However, after his father passed away from Alzheimer’s in 2020, Gates realized the vital role sleep plays …
A recent study revealed that individuals aged 65 and older with Alzheimer’s disease and other forms of dementia account for approximately 7% of all emergency room visits. This study sheds light on the significant impact of dementia-related illnesses on healthcare systems. (Image source: Romy/Pixabay) July 24 (UPI) — A study published in JAMA Neurology revealed …
In a Tuesday morning event, Representative Linda Sánchez (D-Calif.) addressed the issue of the aging population in the United States and its potential impact on Medicare. Sánchez referred to the increasing number of Americans over 65 years old as a “gray tsunami” during The Hill’s event on Alzheimer’s care, sponsored by Otsuka. The Hill’s editor …
Manufacturer Eli Lilly announced on Monday that a second drug, which moderately slows the progression of Alzheimer’s disease, could receive approval by the end of this year. Lilly submitted an application for traditional approval to the Food and Drug Administration (FDA) last quarter and anticipates that the agency will make a decision by the end …
Researchers have reported that a new experimental drug for Alzheimer’s disease, donanemab, can moderately slow the progression of the disease by about four to seven months. Eli Lilly and Co. is currently seeking approval from the Food and Drug Administration for donanemab, which would make it the second Alzheimer’s treatment proven to delay the disease …
Eli Lilly and Company, a pharmaceutical company based in Madrid, Spain, announced on Monday that it has submitted an application for full approval of its Alzheimer’s treatment, donanemab, to the U.S. Food and Drug Administration (FDA). The company anticipates a decision from the FDA by the end of the year. This application is supported by …
The Alzheimer’s drug Leqembi is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai | via Reuters Medicare has reached an agreement to cover the costs of the Alzheimer’s treatment Leqembi, marking a significant milestone for patients in the early stages of the disease. Leqembi is currently the only drug …